Seite auswählen

Illumina Inc. of San Diego, USA has announced the acquisition of Cambridge-based Blue Gnome for an undisclosed fee.

Now fully owned by Illumina, Blue Gnome provides solutions for the screening of genetic abnormalities associated with developmental delay, cancer and infertility.

President and chief executive officer of Illumina, Jay Flatley, stated, ‚The BlueGnome acquisition supports Illumina’s goal to be the leader in genomic-based diagnostics and enhances the company’s ability to establish integrated solutions in reproductive health and cancer. BlueGnome is the leader in the rapidly growing IVF market and is well-known for their software and comprehensive assay workflows.‘

[ilink url=““] Link to Source (Finanz Nachrichten DE)[/ilink]